Contract manufacturer of pharmaceutical formulations, producing dosage forms for other pharma companies in India.
Contract manufacturer of pharmaceutical formulations, producing dosage forms for other pharma companies in India.
In one line: A pharma contract formulation manufacturer.
Moat: none (process know-how). Contract manufacturing scale, but limited pricing power versus branded pharma customers.
Headquarters: India · Employees: 4,131
Size Viyash Scientific (VIYASH.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.11B, the 568th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹235.61 on 18 Nov 2026.
Performance Over six months the shares gained 3.0%, against -11.7% for the median peer and +3.8% for the India market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 123.9% over the last twelve months (peer median -1.5%); the operating margin is 13.1% (peer median 4.5%).
Valuation It trades at 32.2× forward earnings against a peer median of 20.2× (3rd most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 9.3 points below its cost of capital (19.1% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹37.1B | ₹34.2B | ₹30.1B | ₹13.7B | ₹14.2B |
| Revenue growth | — | +14% | +120% | -4% | — |
| Gross profit | ₹11.6B | ₹7.79B | ₹4.80B | ₹1.85B | ₹1.60B |
| EBITDA | ₹7.11B | ₹6.57B | ₹3.94B | ₹649M | ₹460M |
| Net income | ₹2.33B | ₹1.77B | ₹232M | -₹359M | -₹1.21B |
| Free cash flow | n/a | ₹1.29B | ₹1.66B | -₹449M | -₹1.05B |
| Capital expenditure | n/a | ₹1.35B | ₹1.08B | ₹308M | ₹862M |
| Total debt | ₹5.84B | ₹4.90B | ₹6.54B | ₹4.88B | ₹4.44B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Viyash Scientific VIYASH.NS | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% |
| Piramal Pharma PPLPHARMA.NS | $3.40B | +38% | +9% | 3% | 150.8× | n/a |
| Cohance Lifesciences COHANCE.NS | $1.87B | +7% | +14% | 2% | 96.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIYASH.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.6% | -2.3% | 4th highest of 21 |
| 6-month return | +3.0% | -11.7% | 7th highest of 20 |
| Distance from 52-week high | -20.9% | -33.1% | 6th highest of 21 |
| Revenue growth (TTM) | +123.9% | -1.5% | 3rd highest of 18 |
| Operating margin | 13.1% | 4.5% | 6th highest of 19 |
| Forward P/E | 32.2× | 20.2× | 3rd most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 36.3% | 2.9% | 2nd most demanding of 9 |
| Growth delivered (Del g) | +20.4% | +5.4% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | +16.0 pp | +0.3 pp | 2nd most demanding of 9 |
| ROIC minus cost of capital | -9.3 pp | -3.0 pp | 8th lowest of 19 |
| EV / EBITDA | 15.1× | 13.2× | 2nd most expensive of 6 |
| Net debt / EBITDA | 0.1× | -1.7× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |